Your browser doesn't support javascript.
loading
Preserved SARS-CoV-2 Vaccine Cell-Mediated Immunogenicity in Patients With Inflammatory Bowel Disease on Immune-Modulating Therapies.
Boland, Brigid S; Goodwin, Benjamin; Zhang, Zeli; Bloom, Nathaniel; Kato, Yu; Neill, Jennifer; Le, Helen; Tysl, Tiffani; Collins, Angelina E; Dulai, Parambir S; Singh, Siddharth; Nguyen, Nghia H; Grifoni, Alba; Sette, Alessandro; Weiskopf, Daniela; Chang, John T; Dan, Jennifer M.
Afiliação
  • Boland BS; Division of Gastroenterology, University of California, San Diego, La Jolla, California, USA.
  • Goodwin B; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, California, USA.
  • Zhang Z; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, California, USA.
  • Bloom N; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, California, USA.
  • Kato Y; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, California, USA.
  • Neill J; Division of Gastroenterology, University of California, San Diego, La Jolla, California, USA.
  • Le H; Division of Gastroenterology, University of California, San Diego, La Jolla, California, USA.
  • Tysl T; Division of Gastroenterology, University of California, San Diego, La Jolla, California, USA.
  • Collins AE; Division of Gastroenterology, University of California, San Diego, La Jolla, California, USA.
  • Dulai PS; Division of Gastroenterology, University of California, San Diego, La Jolla, California, USA.
  • Singh S; Division of Gastroenterology, University of California, San Diego, La Jolla, California, USA.
  • Nguyen NH; Division of Gastroenterology, University of California, San Diego, La Jolla, California, USA.
  • Grifoni A; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, California, USA.
  • Sette A; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, California, USA.
  • Weiskopf D; Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California, San Diego, La Jolla, California, USA.
  • Chang JT; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, California, USA.
  • Dan JM; Division of Gastroenterology, University of California, San Diego, La Jolla, California, USA.
Clin Transl Gastroenterol ; 13(4): e00484, 2022 04 01.
Article em En | MEDLINE | ID: mdl-35347100
Immune-modulating medications for inflammatory bowel diseases (IBDs) have been associated with suboptimal vaccine responses. There are conflicting data with SARS-CoV-2 vaccination. We therefore assessed SARS-CoV-2 vaccine immunogenicity at 2 weeks after second mRNA vaccination in 29 patients with IBD compared with 12 normal healthy donors. We observed reduced humoral immunity in patients with IBD on infliximab. However, we observed no difference in humoral and cell-mediated immunity in patients with IBD on infliximab with a thiopurine or vedolizumab compared with normal healthy donors. This is the first study to demonstrate comparable cell-mediated immunity with SARS-CoV-2 vaccination in patients with IBD treated with different immune-modulating medications.
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doenças Inflamatórias Intestinais / COVID-19 Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doenças Inflamatórias Intestinais / COVID-19 Idioma: En Ano de publicação: 2022 Tipo de documento: Article